Investors

Recent Releases more »   
Mar 2, 2010 OSI Pharmaceuticals Board of Directors to Review Astellas' Unsolicited Tender Offer
Mar 1, 2010 OSI Pharmaceuticals Confirms Receipt of Unsolicited Proposal From Astellas Pharma
Feb 25, 2010 OSI Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference on Tuesday, March 2, 2010
Corporate Profile

OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for patients with cancer, diabetes, and obesity.

We specialize in the discovery and development of innovative molecular targeted therapies that address significant unmet medical needs, and strive to turn pioneering science into breakthrough therapies for patients suffering from life-threatening diseases.
Stock Quote
OSIP (Common Stock)
Exchange NASDAQ
Price $57.68
Change (%) up0.48 (0.84%)
Volume 1,008,600
As of 03/12/10 4:00 PM ET
Minimum 20 minute delay

Receive E-mail Alerts

RSS Feeds